lung
cancer
lead
caus
cancerrel
mortal
worldwid
lack
tumor
specif
remain
major
drawback
effect
chemotherapi
result
doselimit
toxic
howev
ligandmedi
drug
deliveri
system
abl
render
chemotherapi
specif
tumor
cell
less
toxic
normal
tissu
studi
isol
novel
peptid
ligand
phagedisplay
peptid
librari
bound
nonsmal
cell
lung
cancer
nsclc
cell
line
target
phage
bound
sever
nsclc
cell
line
normal
cell
target
phage
synthet
peptid
recogn
surgic
specimen
nsclc
posit
rate
specimen
sever
combin
immunodefici
scid
mice
bear
nsclc
xenograft
target
phage
specif
bound
tumor
mass
tumor
home
abil
target
phage
inhibit
cognat
synthet
peptid
control
wtymut
peptid
target
peptid
coupl
liposom
carri
doxorubicin
vinorelbin
therapeut
index
chemotherapeut
agent
surviv
rate
mice
human
lung
cancer
xenograft
markedli
increas
furthermor
target
liposom
increas
drug
accumul
tumor
tissu
compar
free
drug
enhanc
cancer
cell
apoptosi
result
higher
concentr
bioavail
doxorubicin
current
studi
suggest
tumorspecif
peptid
may
use
creat
chemotherapi
specif
target
tumor
cell
treatment
nsclc
design
target
gene
transfer
vector
may
use
one
diagnosi
malign
lung
cancer
one
commonli
diagnos
malign
develop
countri
grow
problem
develop
countri
two
major
type
lung
cancer
nonsmal
cell
lung
cancer
nsclc
small
cell
lung
cancer
sclc
nsclc
make
approxim
lung
cancer
case
limit
respons
rate
current
chemotherapeut
agent
tumor
shrinkag
patient
twoyear
surviv
rate
one
major
reason
unsatisfactori
outcom
chemotherapi
compromis
drug
deliveri
lung
cancer
tissu
due
high
interstiti
fluid
pressur
ifp
within
tumor
system
administ
chemotherapi
adequ
deliv
solid
tumor
immatur
vasculatur
abnorm
architectur
leaki
heterogen
vessel
wall
well
high
ifp
within
tumor
tissu
furthermor
lack
tumor
specif
allow
anticanc
drug
distribut
indiscrimin
normal
organ
tissu
thu
cancer
cell
expos
lower
concentr
drug
normal
cell
result
decreas
effect
also
increas
toxic
therefor
import
develop
strategi
enhanc
amount
drug
deliv
tumor
tissu
target
way
spare
normal
tissu
effort
ongo
improv
therapeut
index
anticanc
agent
either
increas
drug
concentr
insid
tumor
decreas
normal
host
tissu
compar
convent
administ
chemotherapeut
agent
lipidor
polymerbas
nanomedicin
drug
deliveri
system
advantag
improv
pharmacolog
therapeut
properti
cytotox
drug
smallmolecul
chemotherapeut
agent
larg
volum
distribut
intraven
administr
narrow
therapeut
window
due
seriou
toxic
normal
tissu
encapsul
drug
nanoparticl
liposom
scientist
significantli
reduc
volum
distribut
increas
concentr
activ
drug
within
tumor
pegyl
liposom
doxorubicin
brand
name
doxil
us
caelyx
europ
shown
significantli
improv
therapeut
index
doxorubicin
preclin
clinic
studi
sever
drug
deliveri
system
kind
approv
market
pegyl
liposom
higher
select
anticanc
activ
achiev
ligandmedi
target
liposom
novel
drug
deliveri
system
target
moieti
coupl
surfac
liposom
promot
select
bind
tumorspecif
antigen
facilit
deliveri
drugcontain
liposom
intend
cellular
site
system
advantag
higher
drugtocarri
ratio
immunoconjug
multival
present
ligand
lead
increas
bind
avid
research
alreadi
produc
liposom
conjug
variou
peptid
ligand
specif
target
certain
tumor
cell
tumor
vasculatur
favor
select
specif
ligandconjug
liposom
anticanc
drug
promis
approach
new
chemotherapi
research
use
peptid
ligand
direct
liposom
tumor
repres
potenti
feasibl
method
increas
specif
effect
liposomecontain
drug
phage
display
techniqu
select
target
peptid
peptid
express
surfac
bacteriophag
fusionprotein
one
virion
coat
protein
phagedisplay
peptid
librari
allow
research
map
proteinprotein
contact
bcell
epitop
receptorligand
interact
peptid
librari
also
use
identifi
organand
celltypespecif
peptid
studi
use
phagedisplay
peptid
librari
identifi
novel
peptid
bound
specif
nsclc
cell
line
surgic
specimen
lung
cancer
patient
liposom
doxorubicin
vinorelbin
conjug
target
peptid
demonstr
enhanc
accumul
drug
tumor
tissu
improv
therapeut
index
human
lung
cancer
xenograft
scid
mice
use
phagedisplay
random
peptid
librari
isol
phage
abl
bind
nsclc
cell
five
round
affin
select
biopan
cell
increas
titer
phage
fig
enrich
phage
third
fifth
biopan
round
randomli
select
sequenc
phage
clone
higher
activ
use
genet
comput
group
gcg
softwar
analysi
found
select
phage
display
consensu
motif
tryptophan
w
threonin
tyrosin
tyrosin
tabl
interestingli
phage
appear
third
fourth
fifth
biopan
round
biopan
round
frequenc
increas
third
cycl
fifth
cycl
tabl
chose
focu
novel
peptid
display
tdsilrsydwti
studi
vitro
phage
display
screen
peptid
bind
nsclc
phagedisplay
random
peptid
librari
use
select
phage
bind
nsclc
cell
line
b
visual
bind
lung
cancer
cell
arrowhead
immunohistochem
stain
control
phage
bind
cell
scale
bar
mm
c
fitclabel
peptid
bound
five
nsclc
cell
line
cell
detect
immunofluoresc
stain
scale
bar
mm
repres
photomicrograph
tumor
section
surgic
specimen
human
lung
cancer
detect
use
arrowhead
biotinyl
c
arrowhead
respect
comparison
control
phage
biotinyl
control
peptid
could
bind
surgic
specimen
b
competit
inhibit
synthet
peptid
e
mutat
peptid
lost
competit
abil
f
scale
bar
mm
identif
phage
clone
specif
bind
nsclc
cell
investig
whether
would
bind
nsclc
cell
use
immunohistochemistri
locat
phage
particl
differ
cell
type
result
show
bound
specif
nsclc
cell
line
includ
fig
arrowhead
control
helper
phage
bind
cell
bound
neither
cancer
cell
line
includ
oral
cancer
sa
nasopharyng
carcinoma
cell
normal
epitheli
cell
nnm
nasal
mucosa
fig
abil
confirm
peptid
competit
inhibit
experi
use
immunofluoresc
stain
result
show
bind
activ
phage
cell
inhibit
synthet
peptid
dosedepend
manner
concentr
mgml
complet
inhibit
bind
activ
fig
control
phage
bind
cell
bind
assay
fig
text
verifi
phage
would
bind
target
molecul
express
surfac
cell
measur
cell
use
flow
cytometri
fig
text
control
phage
use
estim
nonspecif
background
bind
fig
result
show
cell
bound
fig
bind
complet
inhibit
mgml
peptid
fig
bind
sa
nnm
determin
whether
peptid
sequenc
display
would
actual
interact
nsclc
cell
use
fluorescein
isothiocyan
fitc
label
peptid
place
phage
peptidebind
assay
immunofluoresc
stain
specif
bound
nsclc
cell
line
test
includ
bind
nnm
concentr
fitclabel
control
peptid
fitcconp
reveal
bind
activ
fig
also
evalu
magnitud
specif
bind
use
flow
cytometri
proport
cell
bound
respect
fig
text
determin
whether
target
ligand
affin
human
lung
cancer
surgic
specimen
test
reactiv
pulmonari
adenocarcinoma
cell
use
immunohistochemistri
biotinlabel
recogn
tumor
cell
nsclc
surgic
specimen
fig
c
arrowhead
control
phage
biotinlabel
control
peptid
bconp
fig
b
tdsilrsydwti
compet
bind
surgic
specimen
pulmonari
adenocarcinoma
fig
concentr
mutat
peptid
tdsilrsydggg
fig
seventyf
percent
pulmonari
adenocarcinoma
specimen
patient
express
target
molecul
recogn
peptid
tabl
data
indic
could
recogn
unidentifi
molecul
express
nsclc
cell
line
actual
cancer
cell
surgic
specimen
lung
cancer
investig
target
abil
phage
vivo
inject
phage
tail
vein
mice
bear
tumor
recov
perfus
determin
titer
phage
tumor
mass
normal
control
organ
brain
heart
lung
show
specif
home
tumor
mass
concentr
higher
concentr
control
organ
fig
control
helper
phage
show
specif
target
tumor
tissu
fig
tumorhom
abil
confirm
peptid
competit
inhibit
experi
synthet
peptid
inject
togeth
markedli
inhibit
recoveri
phage
tumor
mass
fig
one
hundr
microgram
inhibit
bind
tumor
mass
concentr
control
peptid
inhibitori
effect
fig
vitro
phage
display
screen
identifi
two
clone
consensu
motif
wtyy
tabl
like
tumorhom
abil
also
competit
inhibit
fig
text
suggest
two
phage
may
bind
motif
target
molecul
plasma
membran
lung
cancer
cell
propos
three
amino
acid
residu
might
play
crucial
role
home
tumor
tissu
test
hypothesi
chang
three
amino
acid
residu
tdsilrsydwti
ggg
mutant
peptid
tdsilrsydggg
although
tumorhom
abil
markedli
inhibit
peptid
competit
inhibit
lost
contain
ggg
residu
instead
wti
residu
fig
data
indic
wti
residu
import
bind
abil
nsclc
cell
tissu
distribut
also
studi
use
immunostain
inject
scid
mice
bear
nsclc
xenograft
remov
fix
tumor
control
organ
local
phage
particl
found
local
tumor
tissu
fig
higher
magnif
immunoreact
phage
detect
plasma
membran
diffus
surround
cytoplasm
tumor
cell
fig
reaction
product
detect
normal
organ
brain
heart
lung
tissu
fig
ac
tumor
tissu
treat
control
phage
fig
specif
target
nsclc
xenograft
inhibit
synthet
peptid
vivo
home
experi
fig
determin
whether
lung
cancertarget
peptid
could
use
improv
chemotherapeut
efficaci
cancer
treatment
coupl
peptid
liposom
contain
anticanc
drug
scid
mice
bear
sizematch
xenograft
treat
liposom
doxorubicin
mutant
peptideconjug
liposom
doxorubicin
nontarget
liposom
doxorubicin
ld
free
doxorubicin
fd
equival
volum
phosphatebuff
salin
pb
formul
inject
intraven
iv
total
doxorubicin
dosag
mgkg
mgkg
twice
week
total
eight
inject
tumor
mice
receiv
fig
group
significantli
smaller
ld
fd
pb
group
fig
group
tumor
size
ld
group
time
larger
group
respect
tumor
size
fd
control
pb
group
time
larger
group
respect
fig
interestingli
greater
therapeut
efficaci
lost
wti
motif
peptid
chang
ggg
free
doxorubicin
exhibit
littl
therapeut
efficaci
concentr
tumor
size
group
smaller
pb
group
fig
verifi
whether
larg
xenograft
would
respond
treatment
mice
bear
larg
lung
cancer
xenograft
mm
assign
three
treatment
group
cours
doxorubicin
treatment
total
dosag
mgkg
mgkg
twice
week
eight
inject
tumor
size
control
pb
ld
group
gradual
increas
time
tumor
size
group
fig
result
reveal
also
increas
therapeut
efficaci
doxorubicin
scid
mice
bear
larg
lung
cancer
xenograft
test
whether
would
optim
therapeut
index
lung
cancer
treatment
use
treat
differ
type
lung
cancer
xenograft
tumor
scid
mice
bear
sizematch
xenograft
treat
ld
fd
equival
volum
pb
iv
inject
total
doxorubicin
dosag
mgkg
mgkg
twice
week
eight
inject
final
tumor
size
group
significantli
smaller
ld
fd
pb
group
mice
ld
fd
pb
group
tumor
size
larger
group
fig
free
doxorubicin
concentr
reduc
tumor
size
compar
pb
group
tumor
growth
markedli
suppress
group
fig
bodi
weight
mice
group
increas
g
end
treatment
period
contrast
ldtreat
mice
smaller
increas
bodi
weight
g
fig
confirm
could
increas
therapeut
index
lung
cancer
link
peptid
anoth
anticanc
drug
liposom
vinorelbin
test
efficaci
lung
cancer
xenograft
scid
mice
bear
sizematch
xenograft
given
iv
inject
liposom
vinorelbin
lv
equival
volum
pb
total
vinorelbin
dose
mgkg
mgkg
twice
week
twelv
inject
tumorbear
mice
treat
fig
group
significantli
smaller
tumor
lv
pb
group
fig
group
b
c
tumor
size
lv
group
larger
group
averag
tumor
size
control
pb
group
larger
group
fig
assess
side
effect
treatment
mice
weigh
twice
week
bodi
weight
mice
increas
g
group
g
lv
group
end
treatment
period
data
shown
final
compar
surviv
rate
tumorbear
mice
treatment
lv
pb
day
five
anim
pbstreat
group
die
surviv
rate
three
mice
die
lvtreat
group
surviv
rate
group
howev
surviv
rate
significantli
higher
two
group
fig
experi
demonstr
increas
therapeut
effici
liposomeencapsul
doxorubicin
vinorelbin
less
toxic
biodistribut
tumor
local
ld
fd
estim
measur
intrins
autofluoresc
signal
doxorubicin
mice
nsclc
xenograft
doxorubicin
r
smallmolecul
chemotherapeut
agent
r
poor
pharmacokinet
profil
blood
concentr
drop
background
level
within
one
hour
administr
fig
text
pharmacokinet
profil
variou
liposom
doxorubicin
formul
includ
ld
markedli
greater
fd
fig
area
concentrationtim
curv
auc
hour
doxorubicin
tumor
tissu
mg
hrg
mg
hrg
mg
hrg
mg
hrg
fd
ld
group
respect
tabl
mean
intratumor
doxorubicin
concentr
group
higher
intratumor
doxorubicin
concentr
fd
ld
group
fig
tabl
assess
bioavail
liposom
drug
use
nuclear
doxorubicin
accumul
indic
drug
cytotox
auc
hour
bioavail
doxorubicin
ie
bound
nuclei
fd
ld
mg
hrg
mg
hrg
mg
hrg
mg
hrg
respect
tabl
intratumor
nuclear
doxorubicin
concentr
group
higher
nuclear
doxorubicin
concentr
fd
ld
group
fig
tabl
doxorubicin
concentr
insid
tumor
tissu
nucleu
significantli
differ
ld
group
fig
tabl
compar
drug
deliveri
profil
four
doxorubicin
formul
tri
detect
drug
tumor
tissu
use
fluoresc
microscop
imag
tumor
show
doxorubicin
visual
tumor
nuclei
one
hour
administ
formul
inject
fig
time
area
tumor
section
detect
doxorubicin
increas
area
detect
doxorubicin
significantli
larger
tumor
fd
ld
tumor
time
point
fig
formul
distribut
pattern
ld
region
fdtreat
tumor
show
detect
doxorubicin
fig
tumor
tissu
treatment
group
fig
examin
h
e
stain
markedli
dissemin
necrot
apoptot
area
present
throughout
section
xenograft
fig
addit
termin
deoxynucleotidyl
transferasemedi
dutp
nick
end
label
tunel
use
identifi
apoptot
cell
tomato
lectin
appli
detect
tumor
blood
vessel
tumor
larger
apoptot
area
greater
accumul
anticanc
drug
tumor
tissu
bioavail
doxorubicin
cancer
cell
nuclei
ligandconjug
liposom
demonstr
peptid
recogn
target
molecul
surfac
lung
cancer
cell
thu
increas
direct
drug
deliveri
tumor
therapeut
efficaci
anticanc
drug
achiev
enhanc
drug
formul
molecul
preferenti
bind
tumor
tissu
phage
display
biopan
intact
cell
allow
isol
highli
specif
peptid
target
tumorassoci
antigen
anticanc
regimen
arm
peptid
use
cruis
missil
precis
guid
cancer
cell
deliv
high
enough
dose
kill
cell
minim
damag
normal
tissu
studi
identifi
nsclctarget
peptid
demonstr
improv
therapeut
effici
anim
model
specif
found
phage
clone
made
select
phage
bind
cell
five
round
biopan
tabl
immunohistochemistri
flow
cytometri
assay
confirm
bound
nsclc
cell
surfac
bind
result
observ
cognat
synthet
peptid
replac
fig
fig
experi
support
target
peptid
specif
bind
cell
surfac
nsclc
cell
line
vivo
experi
also
consolid
home
abil
peptid
express
peptid
tdsilrsydwti
guid
phage
accumul
nsclc
xenograft
normal
organ
fig
bind
activ
tumor
tissu
inhibit
synthet
peptid
fig
indic
interact
nsclc
cell
display
peptid
anoth
part
phage
particl
mutat
synthet
peptid
inhibit
bind
demonstr
import
wti
motif
bind
activ
fig
moreov
phenomenon
observ
immunohistochem
stain
surgic
specimen
human
lung
cancer
fig
e
f
anim
model
ligandtarget
chemotherapi
fig
tumor
local
doxorubicin
deliv
target
liposom
fig
immunohistochemistri
assess
pulmonari
adenocarcinoma
surgic
specimen
demonstr
clinic
potenti
imag
probe
identifi
nsclc
drug
deliveri
agent
treatment
nsclc
biotinlabel
detect
pulmonari
adenocarcinoma
surgic
specimen
experi
fig
seventyf
percent
pulmonari
adenocarcinoma
specimen
patient
express
target
molecul
recogn
peptid
tabl
compet
bind
pulmonari
adenocarcinoma
surgic
specimen
fig
confirm
specif
target
ligand
previou
studi
doxorubicin
larg
use
cancer
treatment
broad
spectrum
antitumor
activ
howev
efficaci
doxorubicin
treatment
nsclc
remain
unsatisfactori
respons
rate
part
result
suboptim
dose
within
tumor
due
indiscrimin
drug
distribut
throughout
bodi
sever
toxic
normal
tissu
organ
liposom
encapsul
target
ligand
may
effect
strategi
deliv
drug
directli
tumor
cell
data
reveal
peptid
markedli
increas
therapeut
efficaci
liposom
chemotherapi
result
higher
surviv
rate
mice
human
lung
cancer
xenograft
produc
limit
side
effect
anim
fig
peptid
increas
therapeut
index
doxorubicin
also
vinorelbin
vinca
alkaloid
use
treat
advanc
nsclc
furthermor
observ
decreas
vessel
densiti
substanti
increas
cell
apoptosi
tumor
tissu
target
liposom
treatment
fig
ligandmedi
liposom
formul
potenti
superior
convent
anticanc
therapi
nsclc
vivo
pharmacokinet
studi
mice
show
liposom
doxorubicin
dramat
chang
transport
distribut
doxorubicin
heart
lung
kidney
liver
mice
fig
result
echo
similar
investig
prolong
presenc
liposom
circul
doxorubicin
taken
tumor
cell
convent
doxorubicin
administr
fig
find
confirm
fluoresc
signal
doxorubicin
tumor
tissu
fig
passiv
target
phenomenon
nonligand
conjug
liposom
call
enhanc
permeabl
retent
effect
studi
doxorubicin
concentr
ldtreat
group
three
time
tabl
howev
tumor
group
even
higher
doxorubicin
concentr
higher
ld
group
tabl
bioavail
drug
nuclei
cancer
cell
also
higher
ld
group
tabl
result
indic
peptid
directli
deliv
chemotherapeut
drug
intend
target
enhanc
drug
accumul
tumor
tissu
correl
increas
therapeut
efficaci
fig
peptidefunction
liposom
found
import
clinic
potenti
target
drug
deliveri
system
order
use
clinic
howev
final
target
liposom
construct
need
select
compon
ie
peptid
ligand
conjug
methodolog
liposom
drug
optim
conclus
use
phage
display
peptid
librari
screen
peptid
bind
nsclc
cell
identifi
sever
novel
peptid
includ
specif
bound
cell
surfac
nsclc
cell
vitro
vivo
link
liposom
contain
doxorubicin
vinorelbin
increas
therapeut
efficaci
surviv
rate
mice
human
nsclc
xenograft
enhanc
tumor
apoptosi
decreas
tumor
angiogenesi
quantit
visual
doxorubicin
level
also
show
increas
drug
concentr
tumor
tissu
formul
highlight
enhanc
deliveri
penetr
doxorubicin
tumor
result
indic
tumor
target
peptid
may
use
imag
probe
nsclc
target
ligand
liposom
deliveri
system
increas
efficaci
chemotherapi
nsclc
lung
cancer
cell
line
nasopharyng
carcinoma
cell
line
oral
cancer
cell
line
sa
human
normal
nasal
mucos
epitheli
nnm
cell
use
studi
nnm
cell
primari
cultur
deriv
nasal
polyp
line
obtain
american
type
cultur
collect
line
establish
chu
et
al
cell
grown
rpmi
gibco
ca
usa
contain
fetal
bovin
serum
fb
gibco
ca
usa
co
incub
sa
nnm
cell
grown
dmem
gibco
ca
usa
contain
fb
co
incub
phage
display
biopan
procedur
cell
first
incub
uvtreat
inact
control
helper
phage
insertless
phage
phagedisplay
peptid
librari
new
england
biolab
usa
initi
contain
plaqueform
unit
pfu
ad
bound
phage
elut
lysi
buffer
mm
nacl
mm
trishcl
mm
edta
sodium
deoxychol
sd
ph
ice
elut
phage
pool
amplifi
titer
escherichia
coli
cultur
new
england
biolab
usa
recov
phage
use
input
next
round
pan
describ
previous
nintysixwel
elisa
plate
falcon
ca
usa
seed
either
cancer
control
cell
individu
phage
particl
ad
cellcoat
plate
incub
follow
incub
horseradish
peroxidas
hrp
conjug
mous
monoclon
antibodi
mab
pharmacia
uppsala
sweden
subsequ
peroxidas
substrat
ophenylenediamin
dihydrochlorid
sigma
mo
usa
reaction
stop
absorb
measur
nm
use
elisa
reader
select
phage
clone
analyz
use
dna
sequenc
sequenc
perform
primer
correspond
piii
gene
sequenc
phagedisplay
peptid
sequenc
translat
align
use
gcg
program
synthet
target
peptid
tdsilrsydwti
mutant
peptid
tdsilrsydggg
control
peptid
rlldtnrpllpi
synthes
invitrogen
inc
ca
usa
purifi
use
reversephas
highperform
liquid
chromatographi
puriti
conjug
peptid
fitc
biotin
perform
addit
fitc
biotin
peptid
amino
terminu
compani
cell
plate
grown
confluenc
cover
slip
cover
slip
treat
hydrogen
peroxid
plu
nan
block
endogen
peroxidas
activ
incub
phage
cover
slip
wash
fix
paraformaldehyd
incub
hrplabel
mous
mab
treat
peroxidas
substrat
peptid
bind
assay
mgml
fitclabel
control
peptid
ad
cover
slip
incub
counterstain
hoechst
molecular
probe
usa
mount
mount
solut
vector
ca
usa
cell
examin
leica
univers
microscop
imag
merg
use
simplepci
softwar
cimag
pa
usa
local
peptid
bind
lung
cancer
tissu
frozen
section
nsclc
tissu
prepar
incub
phage
clone
biotinlabel
peptid
peptid
competit
inhibit
assay
phage
mix
synthet
target
mutant
peptid
slide
subject
routin
immunohistochem
stain
surgic
specimen
obtain
tissu
bank
nation
taiwan
univers
hospit
ntuh
approv
institut
review
board
ntuh
vivo
home
experi
tissu
distribut
phage
scid
mice
inject
subcutan
sc
dorsolater
flank
human
nsclc
cell
mice
bear
sizematch
lung
cancer
xenograft
approxim
mm
inject
iv
pfu
target
control
phage
perfus
xenograft
tumor
mous
organ
remov
homogen
phage
bound
tissu
sampl
recov
addit
bacteria
titer
iptgxgal
agar
plate
peptid
competit
inhibit
experi
phage
inject
along
mg
synthet
target
peptid
control
peptid
mutant
peptid
organ
tumor
mass
fix
bouin
solut
sigma
mo
usa
fixat
sampl
embed
paraffin
block
paraffin
section
deparaffin
rehydr
subject
immunostain
use
mous
mab
describ
peptideconjug
liposom
contain
doxorubicin
vinorelbin
prepar
describ
studi
briefli
peptid
coupl
nhspegdsp
nhydroxysuccinimidocarboxylpolyethylen
glycol
mw
deriv
distearoylphosphatidyl
ethanolamin
nof
corpor
japan
molar
ratio
reaction
complet
confirm
quantit
remain
amino
group
use
tnb
trinitrobenzenesulfon
reagent
sigma
mo
usa
doxorubicin
vinorelbin
encapsul
liposom
remot
load
method
concentr
mg
drug
per
mmol
phospholipid
peptidylpegdsp
transfer
preform
liposom
coincub
transit
temperatur
lipid
bilay
peptid
molecul
per
liposom
describ
previous
scid
mice
bear
nsclc
xenograft
mm
inject
tail
vein
variou
formul
liposom
doxorubicin
ld
free
doxorubicin
dose
mgkg
select
time
point
three
mice
group
anaesthet
sacrif
blood
sampl
collect
submaxillari
punctur
plasma
sampl
prepar
perfus
xenograft
tumor
mous
organ
remov
homogen
procedur
isol
tumor
cell
nuclei
extract
nuclear
doxorubicin
carri
accord
previou
report
total
doxorubicin
concentr
measur
use
method
describ
mayer
et
al
total
doxorubicin
quantifi
use
spectrofluorometri
l
ex
nm
l
em
nm
synergi
ht
multidetect
micropl
reader
biotek
instrument
winooski
vt
usa
correct
background
fluoresc
standard
curv
obtain
spike
tissu
extract
deriv
mice
receiv
doxorubicin
tissu
concentr
doxorubicin
express
microequival
per
millilit
plasma
per
gram
tissu
standard
doxorubicin
curv
prepar
control
homogen
follow
extract
procedur
drug
level
estim
basi
doxorubicin
fluoresc
equival
determin
presenc
drug
local
tumor
tissu
doxorubicin
autofluoresc
detect
use
zeiss
axiovert
invert
microscop
w
hbo
mercuri
light
sourc
equip
nm
excit
nm
emiss
filter
set
tissu
section
imag
fluar
na
len
captur
roper
scientif
coolsnap
hq
ccd
camera
imag
captur
signal
depth
subsequ
pseudocolor
anim
model
studi
ligandtarget
therapi
mice
week
age
inject
sc
dorsolater
flank
human
nsclc
cell
mice
sizematch
tumor
approxim
mm
randomli
assign
differ
treatment
group
inject
ld
lv
tail
vein
dosag
mgkg
inject
twice
week
four
week
mgkg
inject
twice
week
six
week
mice
bear
larg
tumor
approxim
mm
treat
eight
time
mgkg
twice
week
four
week
mous
bodi
weight
tumor
size
measur
twice
week
tumor
volum
calcul
use
equat
width
anim
care
carri
accord
guidelin
academia
sinica
taiwan
termin
deoxynucleotidyl
transferasemedi
dutp
nick
end
label
tunel
stain
frozen
tumor
tissu
section
incub
termin
deoxynucleotidyl
transferasemedi
dutp
nick
end
label
reaction
mixtur
roch
diagnost
hour
slide
counterstain
mount
medium
dapi
vector
laboratori
slide
visual
fluoresc
microscop
tissu
remov
treat
mice
fix
paraformaldehyd
embed
paraffin
blood
vessel
detect
stain
lycopersicon
esculentum
tomato
lectin
conjug
biotin
vector
ca
usa
biotinyl
lectin
visual
streptavidinconjug
rhodamin
pierc
il
usa
analyz
data
phage
titer
tumor
volum
bodi
weight
doxorubicin
concentr
use
twosid
unpair
student
ttest
consid
p
valu
signific
analys
valu
repres
deviat
text
support
inform
figur
legend
figur
identif
bind
nsclc
cell
repres
microscopi
imag
cell
stain
propidium
iodid
af
red
monoclon
antibodi
gl
green
merg
mr
bind
cell
g
inhibit
mgml
b
h
n
mgml
c
mgml
j
p
dosedepend
manner
control
phage
bind
cell
e
k
q
cell
respect
scale
bar
mm
figur
tumor
home
abil
phage
scid
mice
bear
nsclc
xenograft
inject
iv
phage
recov
perfus
recoveri
tumor
higher
control
organ
target
activ
tumor
tissu
inhibit
